|1.||Ostrand-Rosenberg, Suzanne: 11 articles (10/2015 - 01/2004)|
|2.||von Hofe, Eric: 10 articles (04/2012 - 07/2005)|
|3.||Kallinteris, Nikoletta L: 8 articles (04/2012 - 06/2004)|
|4.||Xu, Minzhen: 7 articles (04/2012 - 06/2004)|
|5.||Thompson, James A: 5 articles (03/2010 - 03/2004)|
|6.||Lu, Xueqing: 5 articles (07/2009 - 02/2005)|
|7.||Humphreys, Robert E: 5 articles (05/2007 - 06/2004)|
|8.||Baxevanis, Constantin N: 4 articles (09/2015 - 05/2007)|
|9.||Papamichail, Michael: 4 articles (09/2015 - 05/2007)|
|10.||Perez, Sonia A: 4 articles (09/2015 - 05/2007)|
10/15/2013 - "Further improving the immunogenicity, tethering of the inserted target Ag to MHC class II-associated invariant chain (Ii) greatly enhances both the presentation of most target Ags, as well as overall protection against viral infection, such as lymphocytic choriomeningitis virus (LCMV). "
04/01/2013 - "Salmonella Typhimurium infection reduced surface expression of MHC-II, by an invariant chain-independent trafficking mechanism, resulting in accumulation of MHC-II in multi-vesicular bodies. "
08/01/2009 - "Exposure of human B cell lines to VV induced a substantial reduction in cellular expression of the class II chaperone, invariant chain (Ii), during the late stages (i.e., 8-10 h) of infection. "
08/01/2009 - "Diminished intracellular invariant chain expression after vaccinia virus infection."
10/15/2007 - "Thus, infection with rBCG-hcs, but not parental BCG, restored surface expression of mature MHC class II molecules in response to IFN-gamma, presumably as result of MHC class II invariant chain degradation dependent on active Cat S secreted by the bacterium. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2009 - "Improved immuno-genicity of the AE37 Ii-key hybrid peptide has been demonstrated in animal models, ex vivo patient cells, and, most recently, in a Phase I clinical trial in breast cancer patients. "
05/01/2009 - "Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines."
06/01/2004 - "Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer."
07/10/2008 - "We present the results of the first human phase I trial of the Ii-Key hybrid HER-2/neu peptide (AE37) vaccine in disease-free, node-negative breast cancer patients. "
11/01/2012 - "Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients."
|3.||Asthma (Bronchial Asthma)
08/01/2015 - "The cell surface expression level of CD74, the MHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treating MS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibit macrophage migration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. "
05/31/2007 - "To evaluate whether nef alleles derived from perinatally HIV-1-infected children showing no, slow or rapid disease progression differ in their abilities to downmodulate mature MHC-II or to upregulate the invariant chain (Ii) associated with immature MHC-II complexes. "
11/01/2005 - "To establish a transplanted tumor producing HCV NS3 protein in mice and study the therapeutic effect of minigene vaccine based on invariant chain substitution. "
11/01/2005 - "[A study on the inhibitory effect on transplanted tumor growth expressing HCV NS3 protein by HCV minigene vaccine based on invariant chain substitution in mice]."
01/01/2014 - "Major histocompatibility complex (MHC) Class II-positive, invariant chain (Ii)-suppressed tumor cells induce both T helper and cytotoxic T lymphocytes' responses. "
07/23/2009 - "In summary, Ii-Key hybrid modification of the HLA-DR4-restricted HPV16 E7(8-22) MHC class II epitope generates a potent immunotherapeutic peptide vaccine that may have potential for treating HPV16+ cancers in HLA-DR4+ patients."
12/01/2008 - "This absence of an anti-tumor immune response despite MHC II expression is likely due to the presence of invariant chain, in support of the MHCII(+)/Ii(-) paradigm."
|2.||Dermatophagoides farinae antigen f 1
|4.||HLA-DR Antigens (HLA-DR)
|5.||Messenger RNA (mRNA)
|7.||HLA-DQ Antigens (HLA-DQ)
|8.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|10.||Neoplasm Antigens (Tumor Antigens)
|1.||Surgical Instruments (Clip)
|3.||Heterologous Transplantation (Xenotransplantation)